Evidence map›Paper›PMID 40725221›Full record

ArticleInternational journal of molecular sciences2025

Disruption Events in the HPV18

Eirini Agnanti, Dimitris Tsakogiannis, Theologos Papadopoulos, Konstantinos I Arvanitidis, Zaharoula Kyriakopoulou, Ioannis Karakasiliotis, Christine Kottaridi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eirini AgnantiLaboratory of General Microbiology, Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Dimitris TsakogiannisResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.ORCID 0000-0001-6835-8410
Theologos PapadopoulosLaboratory of General Microbiology, Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Konstantinos I ArvanitidisLaboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0003-0639-2474
Zaharoula KyriakopoulouDepartment of Environmental Sciences, School of Technology, University of Thessaly, Gaiopolis Campus, 41500 Larissa, Greece.ORCID 0000-0002-2424-6772
Ioannis KarakasiliotisLaboratory of Biology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0003-3004-8104
Christine KottaridiLaboratory of General Microbiology, Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0003-0979-3871

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus 18 (HPV18) is the second most oncogenic high-risk HPV genotype, after HPV16, and is responsible for about 15% of cervical cancer cases worldwide. The integration of high-risk HPV DNA into the host genome leads to the disruption of the

Indexed as

Human papillomavirus 18Oncogene Proteins, ViralPapillomavirus InfectionsPrecancerous ConditionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAdultAgedFemaleGreeceHumansMiddle Agedoncogene protein E2, Human papillomavirus type 18Oncogene Proteins, ViralE1E2HPV18integration

Identifiers

PMID40725221
PMCPMC12295492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.